695 related articles for article (PubMed ID: 16094360)
1. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
[TBL] [Abstract][Full Text] [Related]
2. Cancer: two in one.
Berns A
Nature; 2005 Aug; 436(7052):787-9. PubMed ID: 16094355
[No Abstract] [Full Text] [Related]
3. Bim is a suppressor of Myc-induced mouse B cell leukemia.
Egle A; Harris AW; Bouillet P; Cory S
Proc Natl Acad Sci U S A; 2004 Apr; 101(16):6164-9. PubMed ID: 15079075
[TBL] [Abstract][Full Text] [Related]
4. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
[TBL] [Abstract][Full Text] [Related]
5. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
6. Gene-hypermutated isoforms of MYC protein: Tumour-suppressor P-53 protective-initiation of apoptosis that normally prevents Burkitt's lymphoma tumorigenesis can be enhanced.
Wiseman A
Med Hypotheses; 2006; 66(5):1046-7. PubMed ID: 16413684
[No Abstract] [Full Text] [Related]
7. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis.
Maclean KH; Dorsey FC; Cleveland JL; Kastan MB
J Clin Invest; 2008 Jan; 118(1):79-88. PubMed ID: 18097482
[TBL] [Abstract][Full Text] [Related]
8. Potential synergism of Bim with p53 in mice with Myc‑induced lymphoma in a mouse lymphoma model.
Shang Q; Zhang D; Guo C; Lin Q; Guo Z; Deng C
Mol Med Rep; 2012 Jun; 5(6):1401-8. PubMed ID: 22446994
[TBL] [Abstract][Full Text] [Related]
9. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt's lymphoma in children.
Wilda M; Bruch J; Harder L; Rawer D; Reiter A; Borkhardt A; Woessmann W
Leukemia; 2004 Mar; 18(3):584-8. PubMed ID: 14712292
[TBL] [Abstract][Full Text] [Related]
11. Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis.
Grabow S; Delbridge AR; Aubrey BJ; Vandenberg CJ; Strasser A
Cell Rep; 2016 Mar; 14(10):2337-47. PubMed ID: 26947081
[TBL] [Abstract][Full Text] [Related]
12. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
13. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line.
Wang Y; Szekely L; Okan I; Klein G; Wiman KG
Oncogene; 1993 Dec; 8(12):3427-31. PubMed ID: 8247547
[TBL] [Abstract][Full Text] [Related]
14. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
Eischen CM; Alt JR; Wang P
Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
[TBL] [Abstract][Full Text] [Related]
15. c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression.
Jiang X; Tsang YH; Yu Q
Int J Biochem Cell Biol; 2007; 39(5):1016-25. PubMed ID: 17331788
[TBL] [Abstract][Full Text] [Related]
16. Role of the translocation partner in protection against AID-dependent chromosomal translocations.
Jankovic M; Robbiani DF; Dorsett Y; Eisenreich T; Xu Y; Tarakhovsky A; Nussenzweig A; Nussenzweig MC
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):187-92. PubMed ID: 19966290
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
Eischen CM; Packham G; Nip J; Fee BE; Hiebert SW; Zambetti GP; Cleveland JL
Oncogene; 2001 Oct; 20(48):6983-93. PubMed ID: 11704823
[TBL] [Abstract][Full Text] [Related]
18. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.
Baudino TA; Maclean KH; Brennan J; Parganas E; Yang C; Aslanian A; Lees JA; Sherr CJ; Roussel MF; Cleveland JL
Mol Cell; 2003 Apr; 11(4):905-14. PubMed ID: 12718877
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
Meng X; Carlson NR; Dong J; Zhang Y
Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
[TBL] [Abstract][Full Text] [Related]
20. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis.
Michalak EM; Jansen ES; Happo L; Cragg MS; Tai L; Smyth GK; Strasser A; Adams JM; Scott CL
Cell Death Differ; 2009 May; 16(5):684-96. PubMed ID: 19148184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
